ID   150057
AC   CVCL_A1VU
SY   150,057
DR   cancercelllines; CVCL_A1VU
DR   Wikidata; Q105505861
RX   PubMed=33143664;
CC   Population: Chinese.
CC   Doubling time: 91.7 +- 12.7 hours (Note=At 10th passage), 76.2 +- 6.7 hours (Note=At 26th passage), 70.4 +- 14.0 hours (Note=At 41th passage) (PubMed=33143664).
CC   Sequence variation: Mutation; HGNC; HGNC:11110; ARID1A; Simple; p.Gln1330Ter (c.3988C>T); Zygosity=Heterozygous (PubMed=33143664).
CC   Sequence variation: Mutation; HGNC; HGNC:3690; FGFR3; Simple; p.Ala281Thr (c.841G>A); ClinVar=VCV002187391; Zygosity=Heterozygous (PubMed=33143664).
CC   Derived from site: In situ; Endometrium; UBERON=UBERON_0001295.
ST   Source(s): PubMed=33143664
ST   Amelogenin: X
ST   CSF1PO: 9,11
ST   D13S317: 8,10
ST   D16S539: 9,13
ST   D5S818: 11
ST   D7S820: 10,11
ST   TH01: 7,9
ST   TPOX: 11
ST   vWA: 16,17
DI   NCIt; C8028; Endometrial clear cell adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   63Y
CA   Cancer cell line
DT   Created: 12-01-21; Last updated: 19-12-24; Version: 7
//
RX   PubMed=33143664; DOI=10.1186/s12885-020-07567-w; PMCID=PMC7607743;
RA   Chang Y.-H., Ding D.-C.;
RT   "A clear cancer cell line (150057) derived from human endometrial
RT   carcinoma harbors two novel mutations.";
RL   BMC Cancer 20:1058.1-1058.12(2020).
//